Patent Yatsopano yaku Japan pa Katemera wa Khansa ya Ovarian

"Ndife okondwa kulengeza chitetezo chowonjezera chaukadaulo cha katemera wa khansa ya ovarian wa Anixa, yemwe adapangidwa ku Cleveland Clinic ndipo akuphunziridwa ku NCI. Ukadaulo wapaderawu ukhoza kukhala katemera woyamba woteteza khansa ya m'mawere, yomwe imakhalabe imodzi mwazovuta kwambiri komanso zovuta kuchiza khansa, "adatero Dr. Amit Kumar, CEO, Purezidenti ndi Chairman wa Anixa Biosciences. "Ngati atachita bwino, katemerayu atha kuletsa khansa ya m'mawere kuti isachitike komanso kupulumutsa odwala kuti asalandire chithandizo chamankhwala komanso maopaleshoni ambiri, ndikupulumutsa miyoyo. Tikuyembekezera kupitiriza ntchito yathu yosamalira odwala ndi chiyembekezo kuti katemerayu awonjezera zida zofunika kuti athe kuthana ndi khansa yovutayi ndipo pamapeto pake asintha odwala ambiri. ”

Katemera wa khansa ya ovarian amayang'ana gawo la extracellular la anti-Müllerian hormone receptor 2 (AMHR2-ED), lomwe limawonetsedwa m'matumbo am'mimba koma limasowa pamene mkazi amafika ndikupita patsogolo pakusiya kusamba. Zindikirani, matenda ambiri a khansa ya m'chiberekero amapezeka pambuyo posiya kusamba, ndipo AMHR2-ED imawonetsedwanso m'makhansa ambiri a ovarian. Polandira katemera ngati wa Anixa's yemwe amalunjika ku AMHR2-ED akafika msinkhu wosiya kusamba, khansa ya m'chiberekero, yomwe kale inali imodzi mwa khansa yachikazi yoopsa kwambiri, ikhoza kupewedwa kuti isayambe.

Ntchito ya preclinical yopititsa patsogolo katemerayo ikupitilira kudzera mu PREVENT Program ku National Cancer Institute (NCI), yomwe imathandizira njira zotsogola zotsogola komanso ma biomarker popewa komanso kupha khansa. Zambiri za Preclinical zofalitsidwa mu Cancer Prevention Research mu 2017 zimathandizira kupita patsogolo kwamaphunziro azachipatala.